Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Feb 03, 2024 12:58pm
217 Views
Post# 35861216

New week, month, day…moving forward

New week, month, day…moving forward

First I agree 100% with notable, there is very strong evidence of a team/ crew/ bunch ..what ever we chose to call those wodeful posters on here..working real hard to discredit any good words to be said about Onc  potential.
Certainly all opinions are welcome. A wise friend of mine years ago said " there is no such thing as a wrong opinion"...
Meaning within your mind, your opinion is yours  to have. The information & outcome could be 100% wrong. However your opinion is just that, 
Stating such as IMHO prefaces your position as an opinion.
Passing an opinion off as facts, becomes missleading etc etc.
More or less everything we know about Onc history is factual, public & can be confirmed.
Anything moving forward regarding phase 3 trials, partnerships, buyouts can only be pieced together using ALL of existing data, trial results, analysts reports & company publications.
The SP has suffered greatly since the PanCan cancellation. That is a fact. The PanCan cancellation was 100% external to Onc that also is a fact.
The PanCan organization, still committed to the $5 million grant to help fund an additional PanCreatic cancer arm of combo- therapy, that also is a fact.
PanCan is a world leader in pancreatic cancer research. They have mutiple locations across the USA with onstaff professionals PHDs & scientists all had input to choose Onc/ Pela as part of their precision promise trial.
That was announced November 2023. Regrettably PanCan did not receive the fenderal funding expected. & neede to re- evaluate ( cancel) their programs going forward.
That is factual not an opinion.
ONC announced publicy at that time the need to re- evaluate how to proceed. 
They did announce & still have posted on all of their web information, that they intend to advance to license enabling studies for MBc & pancreatic cancer. Details TBD within the first half if this year.
regardless of PanCan involvement, none of the science which allowed the precision promise inclusion has changed.
Now? 
On the $$ side of things, they can not fund 2 phase 3 trials without a major change to the financial model.
That is also a fact.
Now.....comes the speculations & opinions.
They have solid results & relationship with Roche, They have indicated the pancreatic trial phase 3 will be cotherapy with Roche.
What is not known? Under what $$$ context?
The MBc phase 3 trial does not indicate any collaborator. Theory , they are waiting to see pending results of the bracelet trial with Pfizer.
Still waiting for final " events" aka deaths to give science data to long term overal survival.
Creating an investors & company paradox. The study group is still alive. Great news for the study, the patients etc.
Bad new for those wanting a quick answer.
ONC has said very little since the PanCan disaster.
The Jan update from CEO was essentially a read from the web site.
They must come up with a $$ plan, very soon.
Mutiple options. 
IMHO, a total buyout is the best option going forward.
How much? Obviously opinions vary. Assuming that opinion comes about, we will know before end of Q1.
licesnsing partership?
Same story, 
Anyone who says that a partnership or buyout is not going to happen, is offering an opinion.
Just as my opinion they will be bought out & annouced 
have a great week all.
 

 

 

 

<< Previous
Bullboard Posts
Next >>